KR20200110678A - 머켈 세포 폴리오마바이러스의 큰 및 작은 t 항원, 핵산 작제물 및 상기 항원으로부터 만들어진 백신, 및 상기 항원을 사용하는 방법 - Google Patents

머켈 세포 폴리오마바이러스의 큰 및 작은 t 항원, 핵산 작제물 및 상기 항원으로부터 만들어진 백신, 및 상기 항원을 사용하는 방법 Download PDF

Info

Publication number
KR20200110678A
KR20200110678A KR1020207023370A KR20207023370A KR20200110678A KR 20200110678 A KR20200110678 A KR 20200110678A KR 1020207023370 A KR1020207023370 A KR 1020207023370A KR 20207023370 A KR20207023370 A KR 20207023370A KR 20200110678 A KR20200110678 A KR 20200110678A
Authority
KR
South Korea
Prior art keywords
seq
group
amino acid
sequence selected
fold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207023370A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 비. 웨이너
엘리자베스 듀퍼렛
Original Assignee
더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 filed Critical 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지
Publication of KR20200110678A publication Critical patent/KR20200110678A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207023370A 2018-01-19 2019-01-18 머켈 세포 폴리오마바이러스의 큰 및 작은 t 항원, 핵산 작제물 및 상기 항원으로부터 만들어진 백신, 및 상기 항원을 사용하는 방법 Ceased KR20200110678A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862619161P 2018-01-19 2018-01-19
US62/619,161 2018-01-19
PCT/US2019/014171 WO2019143921A2 (en) 2018-01-19 2019-01-18 Large and small t antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same

Publications (1)

Publication Number Publication Date
KR20200110678A true KR20200110678A (ko) 2020-09-24

Family

ID=67302504

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207023370A Ceased KR20200110678A (ko) 2018-01-19 2019-01-18 머켈 세포 폴리오마바이러스의 큰 및 작은 t 항원, 핵산 작제물 및 상기 항원으로부터 만들어진 백신, 및 상기 항원을 사용하는 방법

Country Status (11)

Country Link
US (2) US11524065B2 (enExample)
EP (1) EP3740226A4 (enExample)
JP (2) JP7485604B2 (enExample)
KR (1) KR20200110678A (enExample)
CN (2) CN120514835A (enExample)
AU (2) AU2019210063B2 (enExample)
BR (1) BR112020014632A2 (enExample)
CA (1) CA3088374A1 (enExample)
EA (1) EA202091732A1 (enExample)
MX (1) MX2020007676A (enExample)
WO (1) WO2019143921A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019210063B2 (en) * 2018-01-19 2025-03-06 The Wistar Institute Of Anatomy And Biology Large and small T antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same
WO2021247534A2 (en) * 2020-06-01 2021-12-09 The Broad Institute, Inc. Compositions and methods for treating merkel cell carcinoma (mcc) using hla class i specific epitopes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028165A2 (en) * 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
WO2016073595A1 (en) * 2014-11-05 2016-05-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services T cells and dendritic cells for polyomavirus therapy
EP3101134A1 (en) * 2015-06-05 2016-12-07 Apcure SAS Therapeutic vaccine for treating or preventing merkel cell polyoma virus-associated tumors
WO2017060283A1 (en) * 2015-10-06 2017-04-13 Universität Basel Specific immunodominant peptide epitopes for polyomavirus vaccine
AU2019210063B2 (en) * 2018-01-19 2025-03-06 The Wistar Institute Of Anatomy And Biology Large and small T antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same

Also Published As

Publication number Publication date
US20200345830A1 (en) 2020-11-05
AU2025204247A1 (en) 2025-06-26
WO2019143921A3 (en) 2020-04-09
US20230201328A1 (en) 2023-06-29
CN111801111B (zh) 2025-06-10
CN120514835A (zh) 2025-08-22
BR112020014632A2 (pt) 2021-01-05
CA3088374A1 (en) 2019-07-25
MX2020007676A (es) 2020-11-12
CN111801111A (zh) 2020-10-20
AU2019210063B2 (en) 2025-03-06
JP2024096334A (ja) 2024-07-12
EP3740226A2 (en) 2020-11-25
WO2019143921A2 (en) 2019-07-25
JP2021511320A (ja) 2021-05-06
JP7485604B2 (ja) 2024-05-16
US11524065B2 (en) 2022-12-13
EP3740226A4 (en) 2021-10-13
EA202091732A1 (ru) 2020-09-10
AU2019210063A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
JP2024150611A (ja) Ｗｔ１ワクチン
US20220354945A1 (en) Epstein-barr virus nucleic acid constructs and vaccines made therefrom, and methods of using same
JP2019508403A (ja) がんのワクチン及びそれを用いた処置の方法
JP2024096334A (ja) メルケル細胞ポリオーマウイルスのラージおよびスモールｔ抗原、それから作製される核酸構築物およびワクチン、ならびにそれを使用する方法
RU2748903C1 (ru) Противораковые вакцины, нацеленные на prame, и их применения
US20240115680A1 (en) Optimized Synthetic Consensus Immunogenic Compositions Targeting the Follicle Stimulating Hormone Receptor (FSHR)
US20250276051A1 (en) Powassan viral antigens and related compositions, and uses thereof to vaccinate and treat patients
US12194000B2 (en) Optimized synthetic consensus immunogenic compositions targeting chondroitin sulfate proteoglycan 4 (CSPG4)
US20190290751A1 (en) Marburgvirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
KR20200096957A (ko) 서바이빈을 표적으로 하는 암 백신 및 이의 용도
HK40038957A (en) Large and small t antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same
EA045600B1 (ru) Конструкты нуклеиновых кислот и вакцины из больших и малых т-антигенов полиомавируса клеток меркеля и способы их применения

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601